Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin

J Infect Dis. 2015 Jun 1;211(11):1795-9. doi: 10.1093/infdis/jiu807. Epub 2014 Dec 15.

Abstract

We assessed peripheral and liver CXCL10 levels in 15 patients treated with telaprevir/pegylated interferon/ribavirin. Induction of peripheral CXCL10 messenger RNA (mRNA) peaked (mean fold-induction [±SD], 3.1 ± 1.9) between treatment hour 6 and day 2, while induction of intrahepatic CXCL10 mRNA peaked (mean fold-induction [±SD], 1.3 ± 0.54) at hour 10 or day 4. Peripheral CXCL10 levels were higher at treatment hour 10 (P = .032) and day 2 (P = .009) in patients with undetectable virus 2 weeks after treatment initiation. Treatment hour 10 (P = .023) and peak (P = .034) intrahepatic CXCL10 levels were also higher in these patients. CXCL10 did not distinguish treatment responders from nonresponders. In conclusion, CXCL10 identified very rapid virological response in patients treated with a direct-acting antiviral.

Clinical trials registration: NCT00892697.

Keywords: CXCL10; HCV; chemokines; liver inflammation.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Chemokine CXCL10 / analysis
  • Chemokine CXCL10 / blood*
  • Chemokine CXCL10 / genetics
  • Chemokine CXCL10 / metabolism*
  • Female
  • Hepacivirus / drug effects
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / epidemiology
  • Hepatitis C, Chronic / immunology*
  • Humans
  • Interferon-alpha / pharmacology
  • Interferon-alpha / therapeutic use*
  • Liver / chemistry
  • Liver / immunology
  • Liver / metabolism
  • Male
  • Middle Aged
  • Oligopeptides / pharmacology
  • Oligopeptides / therapeutic use*
  • Polyethylene Glycols / pharmacology
  • Polyethylene Glycols / therapeutic use*
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use
  • Ribavirin / pharmacology
  • Ribavirin / therapeutic use*
  • Viral Load / drug effects
  • Young Adult

Substances

  • Antiviral Agents
  • CXCL10 protein, human
  • Chemokine CXCL10
  • Interferon-alpha
  • Oligopeptides
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • telaprevir
  • peginterferon alfa-2a

Associated data

  • ClinicalTrials.gov/NCT00892697